Journal for ImmunoTherapy of Cancer (Nov 2020)
699 A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models
- Bo Zhang,
- Ye Liu,
- Kang Li,
- Yuan Hong,
- Tong Zhang,
- Beibei Jiang,
- Zuobai Wang,
- Yingcai Feng,
- Haiying Li,
- Wenfeng Gong,
- Xing Wang,
- Yajuan Gao,
- Xiaosui Zhou,
- Zilin Wang,
- Hongjia Hou,
- Hanzi Sun,
- Xiaomin Song,
- Xuesong Liu
Affiliations
- Bo Zhang
- Ontario Tobacco Research Unit, University of Toronto, Dalla Lana School of Public Health, Toronto, Ontario, Canada
- Ye Liu
- BeGene (Beijing) Co., Ltd., Beijing, China
- Kang Li
- BeGene (Beijing) Co., Ltd., Beijing, China
- Yuan Hong
- Aff1 grid.410427.40000000419370183Cancer CenterGeorgia Regents University Augusta GA USA
- Tong Zhang
- Aff1 0000 0004 1762 1794grid.412558.fDepartment of Hepatic Surgery and Liver Transplantation CenterThe Third Affiliated Hospital of Sun Yat-sen University Guangzhou China
- Beibei Jiang
- BeGene (Beijing) Co., Ltd., Beijing, China
- Zuobai Wang
- BeGene (Beijing) Co., Ltd., Beijing, China
- Yingcai Feng
- BeGene (Beijing) Co., Ltd., Beijing, China
- Haiying Li
- BeGene (Beijing) Co., Ltd., Beijing, China
- Wenfeng Gong
- BeGene (Beijing) Co., Ltd., Beijing, China
- Xing Wang
- BeGene (Beijing) Co., Ltd., Beijing, China
- Yajuan Gao
- BeGene (Beijing) Co., Ltd., Beijing, China
- Xiaosui Zhou
- BeGene (Beijing) Co., Ltd., Beijing, China
- Zilin Wang
- BeGene (Beijing) Co., Ltd., Beijing, China
- Hongjia Hou
- BeGene (Beijing) Co., Ltd., Beijing, China
- Hanzi Sun
- BeGene (Beijing) Co., Ltd., Beijing, China
- Xiaomin Song
- BeGene (Beijing) Co., Ltd., Beijing, China
- Xuesong Liu
- BeGene (Beijing) Co., Ltd., Beijing, China
- DOI
- https://doi.org/10.1136/jitc-2020-SITC2020.0699
- Journal volume & issue
-
Vol. 8,
no. Suppl 3
Abstract
No abstracts available.
